tiprankstipranks
Trending News
More News >
ReShape Lifesciences (RSLS)
NASDAQ:RSLS

ReShape Lifesciences (RSLS) Price & Analysis

Compare
577 Followers

RSLS Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

9.33%0.13%90.51%
― Other Institutional Investors
90.51% Public Companies and Individual Investors

RSLS FAQ

What was ReShape Lifesciences’s price range in the past 12 months?
ReShape Lifesciences lowest stock price was $2.23 and its highest was $416.04 in the past 12 months.
    What is ReShape Lifesciences’s market cap?
    ReShape Lifesciences’s market cap is $5.82M.
      When is ReShape Lifesciences’s upcoming earnings report date?
      ReShape Lifesciences’s upcoming earnings report date is Aug 18, 2025 which is in 46 days.
        How were ReShape Lifesciences’s earnings last quarter?
        ReShape Lifesciences released its earnings results on May 21, 2025. The company reported $18.98 earnings per share for the quarter, beating the consensus estimate of N/A by $18.98.
          Is ReShape Lifesciences overvalued?
          According to Wall Street analysts ReShape Lifesciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does ReShape Lifesciences pay dividends?
            ReShape Lifesciences does not currently pay dividends.
            What is ReShape Lifesciences’s EPS estimate?
            ReShape Lifesciences’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does ReShape Lifesciences have?
            ReShape Lifesciences has 2,385,960 shares outstanding.
              What happened to ReShape Lifesciences’s price movement after its last earnings report?
              ReShape Lifesciences reported an EPS of $18.98 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -13.514%.
                Which hedge fund is a major shareholder of ReShape Lifesciences?
                Currently, no hedge funds are holding shares in RSLS

                ReShape Lifesciences Stock Smart Score

                Company Description

                ReShape Lifesciences

                ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

                RSLS Earnings Call

                Q4 2025
                0:00 / 0:00
                Earnings Call Sentiment|Positive
                The earnings call highlighted several positive achievements, such as revenue growth, cost reductions, improved profit margins, and strategic agreements aimed at enhancing shareholder value. However, it also acknowledged challenges, such as the contraction in revenue over the nine-month period and competition from GLP-1 pharmaceuticals. Overall, the positive aspects slightly outweigh the negative trends.Read More>
                Similar Stocks
                Company
                Price & Change
                Follow
                Windtree Therapeutics
                cbdMD
                INVO Fertility
                iSpecimen
                Onconetix
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis